Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02697240 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
A Phase 1 study, sponsored by University of Mississippi Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02697240: Completed Phase 1 study, sponsored by University of Mississippi Medical Center.
NCT02697240 is a Phase 1 study that has completed, run by University of Mississippi Medical Center. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02697240, a Phase 1 study, has completed, sponsored by University of Mississippi Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
Sickle cell disease is a genetic red blood cell disorder characterized by vaso-occlusion from sickling of red blood cells, that can lead to pain or organ complications such as acute chest syndrome. Sickle cell disease is associated with low amounts of nitric oxide, a compound important for dilating the blood vessel wall. Citrulline is a substance that is known to increase nitric oxide. The goal of this Phase I study are to find the highest safe dose of continuous IV citrulline that can be given to individuals with sickle cell disease experiencing a sickle cell pain crisis or acute chest syndrome without causing severe side effects.
Primary Outcome
The number and severity of adverse event will be determined according to the NCI Common Terminology Criteria for Adverse Events (CTCAE)
Interventions
- DRUG Intravenous citrulline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
What the finished NCT02697240 record still lists
NCT02697240 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Intravenous citrulline is the first listed.
NCT02697240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02697240 about?
NCT02697240 is a clinical study titled "A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome". Sickle cell disease is a genetic red blood cell disorder characterized by vaso-occlusion from sickling of red blood cells, that can lead to pain or organ complications such as acute chest syndrome. Sickle cell disease is associated with low amounts of nitric oxide, a compound important for dilating ...
What is the current status of trial NCT02697240?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2016-02. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02697240?
The interventions under investigation include: Intravenous citrulline (DRUG).
Who is sponsoring clinical trial NCT02697240?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02697240's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia